DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADB274474
Title:
Nuclear Tubulin: A Novel Target for Breast Cancer Chemotherapy
Descriptive Note:
Final rept. 1 May 1998-30 Apr 2001
Corporate Author:
TEXAS UNIV HEALTH SCIENCE CENTER AT SANANTONIO
Report Date:
2001-05-01
Pagination or Media Count:
274.0
Abstract:
Our research is based on our observation that the beta x isotype of tubulin is found in the nuclei of cultured breast cancer cells. Our goals are to learn the function of beta x and to design a novel anti-tumor drug that will target beta x. We have found that the process by which beta x enters the nucleus is specific for that isotype and that nuclear beta x, while very rare in normal cells, is a characteristic of 80 of all tumors, including 100 of breast tumors. We have found that successful anti-tumor drugs taxol, vinblastine expel beta x from the nuclei of tumor cells. We have also found that the beta x isotype may be involved in making tumor cells resistant to oxidation while the beta x isotype can interact with actin filaments in a process regulated by the beta x isotype. We also synthesized a peptidyl- colchicine derivative designed to target the nucleus. Our results indicate that nuclear beta x may be very important in the diagnosis, prognosis, biology and treatment of breast cancer.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
